Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B. Reply. | N Engl J Med;387(14): 1336-1337, 2022 10 06. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B. Reply.

Chowdary, Pratima; Nathwani, Amit.

Affiliation

Chowdary P; Royal Free Hospital, London, United Kingdom.
Nathwani A; University College London, London, United Kingdom a.nathwani@ucl.ac.uk.

N Engl J Med ; 387(14): 1336-1337, 2022 10 06.

Article in En | MEDLINE | ID: mdl-36198187

Subject(s)

Hemophilia B; Factor IX/genetics; Factor IX/therapeutic use; Genetic Therapy/adverse effects; Hemophilia B/genetics; Hemophilia B/therapy; Humans

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hemophilia B Limits: Humans Language: En Journal: N Engl J Med Year: 2022 Document type: Article Affiliation country: United kingdom Country of publication: United States

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hemophilia B Limits: Humans Language: En Journal: N Engl J Med Year: 2022 Document type: Article Affiliation country: United kingdom Country of publication: United States